Evidence map›Paper›PMID 34035721›Full record

ArticleGastroenterology & hepatology2020

Treatment of Refractory Gastroesophageal Reflux Disease.

Rishi D Naik, Matthew H Meyers, Michael F Vaezi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. What goes down may come up: regurgitative behaviors and their underlying gut-brain axes-insights from genetic models and related pathologies.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Neuromodulation for Gastroesophageal Reflux Disease: A Systematic Review.Journal of translational gastroenterology · 2023
    Article
  9. Study on the Effect of Different Endoscopic Auxiliary Treatment of Gastric Mucosal Microtumor.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rishi D NaikDr Naik is an assistant professor of medicine and Dr Vaezi is a professor of medicine, clinical director, and director of the Center for Swallowing and Esophageal Disorders in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Matthew H MeyersDr Naik is an assistant professor of medicine and Dr Vaezi is a professor of medicine, clinical director, and director of the Center for Swallowing and Esophageal Disorders in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Michael F VaeziDr Naik is an assistant professor of medicine and Dr Vaezi is a professor of medicine, clinical director, and director of the Center for Swallowing and Esophageal Disorders in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Vanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroesophageal reflux disease (GERD) is a common disorder that is treated with lifestyle modification, weight loss, and medications, such as proton pump inhibitors (PPIs). An empiric course of PPI therapy is an effective and cost-effective strategy for the management of GERD. However, in some patients, PPI therapy and lifestyle changes are inadequate to control symptoms. When there is persistence of symptoms despite empiric therapy, patients are labeled as having refractory GERD. This label underestimates the wide differential diagnosis of foregut pathology that can mimic symptoms of GERD. A careful history of symptoms, response to PPI therapy, adherence, compliance, and timing helps elucidate if medication has been helping. When patients are refractory, alternative etiologies of GERD must be considered. Many of these alternatives can be determined on an upper endoscopy or with complementary testing, such as high-resolution esophageal manometry or gastric emptying testing as symptoms dictate. When an alternative cause is not found and index endoscopy is normal, additional testing with either traditional pH or impedance testing can be completed based on prior examination results and response to therapy. Further therapy, including medical, endoscopic, or surgical, can then be targeted at the etiology.

Indexed as

antireflux surgeryfunctional esophageal disordersGastroesophageal reflux diseaseimpedance testingproton pump inhibitorsrefractory gastroesophageal reflux disease

Identifiers

PMID34035721
PMCPMC8132683
OpenAlexW3165778231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.